Therapeutics Archives - Page 152 of 175

Adagene Announces First Patient Dosed in United States and Acceptance of IND in China for ADG-106

October 31, 2018

SUZHOU, China, Oct. 31, 2018 /PRNewswire/ — Adagene, Inc., an innovative antibody engineering and discovery company, today announced the dosing of its first patient in its Phase I trial in American for its lead product ADG-106, a fully human agonistic monoclonal antibody (mAb) targeting a novel epitope of CD137. Adagene is also announcing a record speed of review and acceptance of their IND in China for ADG-106. Adagene will investigate the safety and efficacy of ADG-106 therapy as a single agent across a range of solid tumor and non-Hodgkin lymphoma patients in the Phase I clinical study.

“I have worked on this target previously and believe 4-1BB agonists have tremendous therapeutic potential in immunotherapy by targeting the costimulatory pathway,” said Anthony W. Tolcher, M.D., FRCPC, Founder, CEO and Director of Clinical Research at NEXT Oncology (San Antonio, Texas) and an investigator on the trial. “Our team is eager to evaluate ADG-106 because it has shown both excellent safety and efficacy in numerous native preclinical models, and we look forward to assessing the clinical benefit of ADG-106 via its novel mechanism of action that would potentially expand the opportunity for patients to benefit from a novel IO target in both single and combinational therapy.”

“The initiation of a Phase I clinical study of ADG-106 is a pivotal milestone for Adagene and our novel approach to improving cancer care,” said Peter Luo, CEO of Adagene. “Also, we are honored to receive the IND approval from the NMPA (National Medical Products Administration) in an expedited time. We believe it shows their commitment to support drugs with novel biology and mechanism of action. The preclinical evidence shows we are targeting a novel epitope and the antibody behaves very differently compared with the other two monoclonal antibodies previously in the clinic.”

Orchard Therapeutics Announces Pricing of Initial Public Offering

October 30, 2018

BOSTON and LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) — Orchard Therapeutics plc (Nasdaq:ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies, today announced the pricing of its initial public offering in the United States of 14,285,715 American Depositary Shares (“ADSs”) representing 14,285,715 ordinary shares at an initial public offering price of $14.00 per ADS, before underwriting discounts and commissions. In addition, Orchard has granted the underwriters a 30-day option to purchase up to an additional 2,142,857 ADSs at the initial public offering price, less the underwriting discounts and commissions. Orchard’s ADSs are expected to begin trading on The Nasdaq Global Select Market on October 31, 2018, under the ticker symbol “ORTX.” Each of the ADSs are being offered by Orchard. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Orchard, are expected to be $200.00 million, excluding any exercise of the underwriters’ option to purchase additional ADSs. The offering is expected to close on November 2, 2018, subject to the satisfaction of customary closing conditions.

Innovent Biologics Raises $421 Million in Hong Kong IPO

October 25, 2018

Innovent Biologics Inc., a Chinese biotech firm backed by Temasek Holdings Pte, raised HK$3.3 billion ($421 million) after pricing its Hong Kong initial public offering near the top of a marketed range, people with knowledge of that matter said.

The Suzhou-based company priced it sale of 236.35 million shares at HK$13.98 apiece, the people said, asking not to be identified because the information is private. The shares were marketed at HK$12.50 to HK$14 each.

Innovent’s offering will add to the $32 billion of first-time shares sales in Hong Kong this year, almost three times the amount during the same period in 2017, data compiled by Bloomberg show. This year’s three biotech offerings, from BeiGene Ltd., Ascletis Pharma Inc. and Hua Medicine, are all trading below offer price, the data show.

An external spokeswoman for Innovent said she couldn’t immediately comment.

Innovent’s final price implies a market value of $2 billion, according to terms for the deal obtained by Bloomberg earlier. The company expects to begin trading Oct. 31, a prospectus shows.

Kyruus Announces Launch of ProviderMatch for Salesforce on the Salesforce AppExchange to Help Health Systems Deliver Optimal Access Experience

October 23, 2018

BOSTON–(BUSINESS WIRE)–Kyruus, a leader in provider search and scheduling solutions for health systems, today announced the availability of ProviderMatch for Salesforce, which integrates into Salesforce Health Cloud on the Salesforce AppExchange. The solution enables access centers to deliver a personalized, end-to-end patient experience by combining Salesforce’s 360 degree view of the patient with Kyruus’ robust matching, appointment booking, and provider data management capabilities.

The launch of ProviderMatch for Salesforce accompanies a strategic investment in Kyruus from Salesforce Ventures, the global CRM leader’s corporate investment group. With access centers serving as a key “front door” to health systems, the two companies have already seen significant demand for the combined offering of ProviderMatch and Health Cloud.

“In healthcare, customer relationship management starts with the first point of contact – when a patient seeks access to care at a health system,” said Matt Garratt, Managing Partner at Salesforce Ventures. “Kyruus has built a platform that enables health systems to match and book patients with the right providers. We’re especially excited to invest in the company because they’re unique in facilitating this service across all access points.”

Gene therapy biotech Orchard Therapeutics sets terms for $200 million IPO

October 23, 2018

Orchard Therapeutics, which is developing stem cell gene therapies for rare diseases, announced terms for its IPO on Tuesday.

The London, United Kingdom-based company plans to raise $200 million by offering 13.3 million ADSs at a price range of $14 to $16. At the midpoint of the proposed range, Orchard Therapeutics would command a fully diluted market value of $1.4 billion.

Orchard Therapeutics was founded in 2015 and plans to list on the Nasdaq under the symbol ORTX. J.P. Morgan, Goldman Sachs and Cowen are the joint bookrunners on the deal. It is expected to price during the week of October 29, 2018.

US HealthVest is Developing a New Behavioral Hospital on Hendricks Regional Health Plainfield Campus

October 17, 2018

INDIANAPOLIS, Oct. 17, 2018 /PRNewswire/ — US HealthVest announced the development of Indianapolis Behavioral Hospital, a new stand-alone behavioral hospital that will provide a full continuum of specialized inpatient and outpatient mental health care to patients of all ages. The new hospital will be located on the campus of Hendricks Regional Health in Plainfield, Indiana.

“We are excited to work in collaboration with Hendricks Regional Health to bring these vital services to the community,” said Richard Kresch, M.D., President and CEO of US HealthVest. “Indianapolis Behavioral Hospital will treat the increasing and unmet need for specialized mental health services in the growing Indianapolis area.”

The facility will provide behavioral health and addiction treatment services to all patients, regardless of ability to pay. Comprehensive services will include free 24/7 assessments, inpatient care and intensive outpatient services. A full range of specialized programs will be offered, such as a Women’s Program, a Youth Program, a Co-Occurring Disorders Program, a Geriatric Program and a Psychiatric Intensive Care Program.

Devoted Health, New Medicare Advantage Business, Raises $300 Million

October 16, 2018

As open enrollment for Medicare began Monday, in one of the largest healthcare company fundraises of the year, Medicare Advantage business Devoted Health says it’s raised $300 million in a Series B round led by Andreessen Horowitz.

“The problem is the fact that the system itself is fundamentally not designed in a patient-centric way,” wrote cofounder Ed Park in a post on LinkedIn Tuesday. “People are stuck ping-ponging among an assortment of well-meaning primary care doctors, specialists, hospitals, and other facilities, resulting in a patient experience that is highly uncoordinated, fragmented, and reactive, compounded by administrative hassles that seem to emerge from every corner.”

TraceLink Announces Availability of End-to-End DSCSA Saleable Returns Verification Solution for Pharmaceutical Manufacturers and Wholesale Distributors

October 16, 2018

NORTH READING, Mass., Oct. 16, 2018 /PRNewswire/ — TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced availability of its end-to-end saleable returns verification solution for pharmaceutical manufacturers and wholesale distributors, including a verification router service (VRS) and master data sharing capabilities built on its new Product Information Manager network application, as well as Edge functionality for processing saleable returns. TraceLink will be showcasing the solution this week at the Healthcare Distribution Alliance (HDA) Traceability Seminar in Washington DC.

For pharmaceutical manufacturers, TraceLink’s new saleable returns verification solution with master data sharing can be used to distribute product master data to direct and indirect trading partners, while the VRS enables the ability to respond to wholesaler verification requests. For wholesalers, the solution is used to access product master data from its suppliers and VRS is employed to look up the location of a manufacturer’s VRS and to submit verification requests. In the warehouse, TraceLink’s Smart Inventory Tracker and Serialized Event Manager facilitate the scanning and verification of serialized returns that can be resold. The pre-integrated set of applications with master data sharing, VRS, serialized event management and mobile scanning provide wholesalers with a full, end-to-end solution suite for meeting the November 2019 Drug Supply Chain and Security Act (DSCSA) saleable returns requirement.

PatientPing’s National Community of ACO Providers Generate More than $270 Million in Shared Savings

October 10, 2018

Care coordination technology company aids its ACO provider network in achieving significant shared savings for 2017

BOSTON, Oct. 10, 2018 /PRNewswire/ — PatientPing, a health technology company that connects providers to seamlessly coordinate patient care, would like to congratulate its national network of Accountable Care Organizations (ACOs) for generating more than $270 million in shared savings in 2017 in the Medicare Shared Savings Program (MSSP). The care coordination technology company’s ACO network includes thousands of providers that participate in the MSSP and other innovative value-based-care delivery models.

“Patients transitioning across care settings are most at risk for readmissions, medication errors, and changes in providers, which can all lead to undesirable health outcomes and high costs,” said Denise Patriaco, Administrative Director at Hackensack Alliance ACO. “At Hackensack Alliance, we want to be sure that we keep a hand on the patient as they move from the hospital or ER to subacute care and then back home, with or without home health services. PatientPing has allowed us to keep track of a much larger segment of our population than we were able to before and has greatly assisted our ACO in decreasing overall readmissions.”

Buoy Health Named to CNBC’s 2018 Upstart 100 List Highlighting Innovation and Rapid Growth

October 9, 2018

BOSTON–(BUSINESS WIRE)–Oct 9, 2018–Buoy Health, an AI health assistant that helps people from the moment they get sick start their care on the right foot, today announced they have been named to CNBC’s inaugural 2018 Upstart 100 list. The CNBC Upstart 100 list highlights technology-driven start-ups that are experiencing rapid growth due to their innovative products, apps, tools or services. From hundreds of companies nominated from across the country, CNBC selected Buoy Health and its innovative artificial intelligence (AI) health assistant platform as one of the 100 up-and-coming companies with the potential to revolutionize, transform, and disrupt its industry.

Patients using Buoy Health simply visit www.buoyhealth.com and engage in a conversation with its friendly AI health assistant in an exchange designed to mirror a conversation with a doctor. Patients are then prompted through a series of questions to enter their symptoms in detail. Buoy will then analyze the patient’s inputs in real-time and direct the customer to a recommended course of treatment.

Blog

Category: Therapeutics